PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
39707.24%
G&A growth while CRON.TO reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42213.03%
Operating expenses growth while CRON.TO reduces costs. John Neff would investigate differences.
39675.25%
Total costs growth while CRON.TO reduces costs. John Neff would investigate differences.
15324.18%
Interest expense growth above 1.5x CRON.TO's 123.37%. Michael Burry would check for over-leverage.
No Data
No Data available this quarter, please select a different quarter.
-37386.56%
EBITDA decline while CRON.TO shows 23.47% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-5650.01%
Operating income decline while CRON.TO shows 11.40% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-570772.46%
Other expenses reduction while CRON.TO shows 132.19% growth. Joel Greenblatt would examine advantage.
-40472.45%
Pre-tax income decline while CRON.TO shows 18.08% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-40472.45%
Net income decline while CRON.TO shows 18.08% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-3050.00%
EPS decline while CRON.TO shows 17.83% growth. Joel Greenblatt would examine position.
-3050.00%
Diluted EPS decline while CRON.TO shows 17.83% growth. Joel Greenblatt would examine position.
1209.23%
Share count increase while CRON.TO reduces shares. John Neff would investigate differences.
1209.23%
Diluted share increase while CRON.TO reduces shares. John Neff would investigate differences.